Exploring the efficacy of negative pressure wound therapy in the management of mycobacterium ulcerans wounds: a comprehensive literature review

Abstract

Mycobacterium ulcerans (M Ulcerans) infection leads to the debilitating Buruli ulcer (BU), characterized by necrotizing skin and soft tissue lesions. Conventional treatment primarily focuses on an antibiotic regimen, but wound management remains paramount to patient recovery. This literature review aims to evaluate the efficacy and benefits of Vacuum Assisted Dressing (VAC) in the treatment and management of BU wounds. A systematic literature search was undertaken using databases such as PubMed, Cinahl, Cochrane database, Joanna Briggs Institute, Medline, Internurse, Nursing & Allied Health database, and Scopus search from January 1995 to December 2023. The key search terms included “Mycobacterium ulcerans”, OR “Buruli ulcer”, AND “vacuum assisted dressing”, “vacuum assisted therapy”, “Vacuum Assisted Dressing”, “negative pressure wound therapy”, and “Negative Pressure Wound Therapy (NPWT)”. The exclusion criteria were animal studies and studies not in the English language. The current literature emphasizes the importance of antibiotic treatment for BU and highlights the skin and soft tissue damage that results in open, infected wounds. However, there is a notable lack of quantitative data on the efficacy of NPWT for treating BU wounds. Early evidence indicates that NPWT might accelerate wound healing, decrease secondary infections, and enhance wound bed readiness for grafting or secondary healing. While more comprehensive quantitative studies are warranted, NPWT emerges as a promising adjunctive therapy in the holistic management of BU wounds, offering benefits that may improve patient outcomes and reduce morbidity.

Keywords

Vacuum-assisted closure / negative pressure wound therapy / Mycobacterium ulcerans / Buruli ulcer disease / wound

References

[1] Bretzel G.PCR detection of Mycobacterium ulcerans-significance for clinical practice and epidemiology.Expert Rev Mol Diagn2018;18:1063-74

[2] Cozza V,Cintoni M.Vacuum-assisted closure (VAC®) systems and microbiological isolation of infected wounds.World J Emerg Surg2018;13:53 PMCID:PMC6245752

[3] Huang C,Bayer LR.Effect of negative pressure wound therapy on wound healing.Curr Probl Surg2014;51:301-31

[4] Yoo JY,Kim JS,Ki JS.Clinical nurses’ beliefs, knowledge, organizational readiness and level of implementation of evidence-based practice: The first step to creating an evidence-based practice culture.PLoS One2019;14:e0226742 PMCID:PMC6932768

[5] Janssen AHJ,Notter J,Wegdam JA.Negative pressure wound therapy versus standard wound care on quality of life: a systematic review.J Wound Care2016;25:154-9

[6] Loftus MJ,Crouch S,Johnson PD.A non-healing ulcer in a healthy young woman.Aust Fam Physician2017;46:855-6

[7] Moore K. VAC therapy: interactions in the healing process. Available from: https://wounds-uk.com/wp-content/uploads/sites/2/2023/02/content_9001.pdf. [Last accessed on 22 Aug 2024]

[8] Muleta AJ,Stinear TP.Understanding the transmission of Mycobacterium ulcerans: a step towards controlling Buruli ulcer.PLoS Negl Trop Dis2021;15:e0009678 PMCID:PMC8389476

[9] Murase C,Nakanaga K,Akiyama M.Buruli ulcer successfully treated with negative-pressure wound therapy.JAMA Dermatol2015;151:1137-9

[10] O'Brien DP,Cowan R,Athan E.Six vs eight weeks of antibiotics for small mycobacterium ulcerans lesions in australian patients.Clin Infect Dis2020;70:1993-7

[11] O’Brien DP,Buntine J.Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update.Med J Aust2014;200:267-70

[12] Pittet LF, Tebruegge M, Dutta B, et al; BCG Immune Response Study (BIRS) group. Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine.Vaccine2021;39:652-7

[13] Pluschke G.Mycobacterium ulcerans: methods and protocols. New York, USA: Humana Press; 2022.

[14] Saaiq M., Hameed-Ud-Din, Khan M I, Chaudhery SM. Vacuum-assisted closure therapy as a pre-treatment for split thickness skin grafts.J Coll Physicians Surg Pak2010;20:675-9

[15] Sizaire V,Comte E.Mycobacterium ulcerans infection: control, diagnosis, and treatment.Lancet Infect Dis2006;6:288-96

[16] Suzuki K,Miyamoto Y.Buruli Ulcer in Japan. In: Pluschke G, Röltgen K, editors. Buruli ulcer. Cham: Springer; 2019. pp. 87-105.

[17] Tai AYC,Friedman ND,Walton A.Increased severity and spread of mycobacterium ulcerans, Southeastern Australia.Emerg Infect Dis2018;24:58-64 PMCID:PMC5749465

[18] Van Der Werf TS, Barogui YT, Converse PJ, Phillips RO, Stienstra Y. Pharmacologic management of Mycobacterium ulcerans infection.Expert Rev Clin Pharmacol2020;13:391-401 PMCID:PMC9020253

[19] Velding K,Abass KM,Stienstra Y.The application of modern dressings to Buruli ulcers: results from a pilot implementation project in Ghana.Am J Trop Med Hyg2016;95:60-2 PMCID:PMC4944710

[20] Yotsu RR,Ishii N.Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).Cochrane Database Syst Rev2018;8:CD012118 PMCID:PMC6513118

[21] Xu S,Chen J.Stretchable fiber strain sensors for wearable biomonitoring.Natl Sci Rev2024;11:nwae173 PMCID:PMC11173172

[22] Johnson PDR,Lavender CJ.Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia.Emerg Infect Dis2007;13:1653-60 PMCID:PMC3375796

[23] Seth I,Lim B.Advancements, applications, and safety of negative pressure wound therapy: a comprehensive review of its impact on wound outcomes.Plast Aesthet Res2024;11:29